Artiva Biotherapeutics, Inc. (ARTV) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 251K | 2.35M |
| Revenue Growth % | - | - | - | - | -100% | -100% | - | - | - | - |
| Cost of Goods Sold | 666K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -666K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 251K | 2.35M |
| Gross Margin % | - | - | - | - | - | - | - | - | 100% | 100% |
| Gross Profit Growth % | - | - | - | - | -100% | -100% | - | - | - | - |
| Operating Expenses | 23.76M | 21.93M | 22.9M | 22.81M | 22.17M | 18.27M | 18.34M | 16.19M | 14.74M | 14.32M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | 5873.71% | 609.36% |
| Selling, General & Admin | 5.12M | 4.94M | 5.26M | 4.95M | 5.12M | 4.95M | 4.81M | 3.86M | 3.59M | 3.17M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | 1429.08% | 134.77% |
| Research & Development | 19.31M | 16.99M | 17.63M | 17.86M | 17.05M | 13.32M | 13.52M | 12.33M | 11.16M | 11.15M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | 4444.62% | 474.6% |
| Other Operating Expenses | -666K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -24.43M | -21.93M | -22.9M | -22.81M | -22.17M | -18.27M | -18.34M | -16.19M | -14.49M | -11.97M |
| Operating Margin % | - | - | - | - | - | - | - | - | -5773.71% | -509.36% |
| Operating Income Growth % | -10.19% | -20.06% | -24.88% | -40.89% | -52.99% | -52.61% | - | - | - | - |
| EBITDA | -23.76M | -21.27M | -22.23M | -22.17M | -21.54M | -17.65M | -17.71M | -15.59M | -13.9M | -11.38M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | -5539.84% | -484.09% |
| EBITDA Growth % | -10.31% | -20.47% | -25.56% | -42.23% | -54.93% | -55.18% | - | - | - | - |
| D&A (Non-Cash Add-back) | 666K | 666K | 662K | 641K | 628K | 614K | 627K | 603K | 587K | 594K |
| EBIT | -24.43M | -21.93M | -22.9M | -22.81M | -22.17M | -18.27M | -18.34M | -16.19M | -14.49M | -11.97M |
| Net Interest Income | 912K | 1.16M | 1.37M | 1.56M | 1.86M | 2.18M | 1.85M | 676K | 650K | 583K |
| Interest Income | 912K | 1.16M | 1.37M | 1.56M | 1.86M | 2.18M | 1.85M | 676K | 650K | 583K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 914K | 1.16M | 1.37M | 1.56M | 1.86M | 9.05M | 863K | -1.65M | 529K | 44K |
| Pretax Income | -23.52M | -20.77M | -21.53M | -21.25M | -20.31M | -9.21M | -17.47M | -17.84M | -13.96M | -11.93M |
| Pretax Margin % | - | - | - | - | - | - | - | - | -5562.95% | -507.49% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 72K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -0.6% |
| Net Income | -23.52M | -20.77M | -21.53M | -21.25M | -20.31M | -9.21M | -17.47M | -17.84M | -13.96M | -12M |
| Net Margin % | - | - | - | - | - | - | - | - | -5562.95% | -510.55% |
| Net Income Growth % | -15.78% | -125.42% | -23.21% | -19.12% | -45.46% | 23.2% | - | - | - | - |
| Net Income (Continuing) | -23.52M | -20.77M | -21.53M | -21.25M | -20.31M | -9.21M | -17.47M | -17.84M | -13.96M | -12M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.95 | -0.85 | -0.88 | -0.87 | -0.83 | -0.82 | -0.92 | -0.62 | -0.79 | -0.54 |
| EPS Growth % | -14.46% | -3.66% | 4.35% | -40.32% | -5.06% | -51.85% | - | - | - | - |
| EPS (Basic) | -0.95 | -0.85 | -0.88 | -0.87 | -0.83 | -0.82 | -0.92 | -0.62 | -0.79 | -0.54 |
| Diluted Shares Outstanding | 24.68M | 24.44M | 24.48M | 24.38M | 24.34M | 24.36M | 24.29M | 23.28M | 17.58M | 20.43M |
| Basic Shares Outstanding | 24.68M | 24.44M | 24.48M | 24.38M | 24.34M | 24.36M | 24.29M | 23.28M | 17.58M | 20.43M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |